Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Phase 2 Trial of Emrusolmin in Multiple System Atrophy
2025-521642-14-00Phase 2Authorised
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of emrusolmin in multiple system atrophy (MSA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Adverse events incidence and Withdrawals due to adverse events. Planned start Feb 2026; status: authorised.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2025-521642-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521642-14-00.